vs

Side-by-side financial comparison of Enact Holdings, Inc. (ACT) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.

Enact Holdings, Inc. is the larger business by last-quarter revenue ($312.7M vs $209.6M, roughly 1.5× Varex Imaging Corp). On growth, Varex Imaging Corp posted the faster year-over-year revenue change (4.9% vs 3.6%). Over the past eight quarters, Enact Holdings, Inc.'s revenue compounded faster (3.6% CAGR vs 0.8%).

Enact Holdings, Inc. is a leading U.S.-based private mortgage insurance provider. It delivers risk mitigation solutions to residential mortgage lenders, banks, and credit unions, enabling borrowers with smaller down payments to access affordable home financing, and supports sustainable homeownership for diverse consumer groups across the United States.

Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.

ACT vs VREX — Head-to-Head

Bigger by revenue
ACT
ACT
1.5× larger
ACT
$312.7M
$209.6M
VREX
Growing faster (revenue YoY)
VREX
VREX
+1.3% gap
VREX
4.9%
3.6%
ACT
Faster 2-yr revenue CAGR
ACT
ACT
Annualised
ACT
3.6%
0.8%
VREX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACT
ACT
VREX
VREX
Revenue
$312.7M
$209.6M
Net Profit
$2.3M
Gross Margin
33.3%
Operating Margin
71.3%
7.3%
Net Margin
1.1%
Revenue YoY
3.6%
4.9%
Net Profit YoY
866.7%
EPS (diluted)
$1.23
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACT
ACT
VREX
VREX
Q1 26
$209.6M
Q4 25
$312.7M
$228.9M
Q3 25
$311.5M
$203.0M
Q2 25
$304.9M
$212.9M
Q1 25
$306.8M
$199.8M
Q4 24
$301.8M
Q3 24
$309.6M
$205.7M
Q2 24
$298.8M
$209.1M
Net Profit
ACT
ACT
VREX
VREX
Q1 26
$2.3M
Q4 25
$12.2M
Q3 25
$-89.1M
Q2 25
$6.9M
Q1 25
$-300.0K
Q4 24
Q3 24
$-51.1M
Q2 24
$1.4M
Gross Margin
ACT
ACT
VREX
VREX
Q1 26
33.3%
Q4 25
34.0%
Q3 25
33.3%
Q2 25
36.0%
Q1 25
34.3%
Q4 24
Q3 24
32.6%
Q2 24
32.0%
Operating Margin
ACT
ACT
VREX
VREX
Q1 26
7.3%
Q4 25
71.3%
8.6%
Q3 25
67.4%
-39.8%
Q2 25
70.4%
10.4%
Q1 25
68.9%
5.6%
Q4 24
68.9%
Q3 24
74.1%
5.3%
Q2 24
78.6%
4.4%
Net Margin
ACT
ACT
VREX
VREX
Q1 26
1.1%
Q4 25
5.3%
Q3 25
-43.9%
Q2 25
3.2%
Q1 25
-0.2%
Q4 24
Q3 24
-24.8%
Q2 24
0.7%
EPS (diluted)
ACT
ACT
VREX
VREX
Q1 26
$0.05
Q4 25
$1.23
$0.29
Q3 25
$1.10
$-2.15
Q2 25
$1.11
$0.17
Q1 25
$1.08
$-0.01
Q4 24
$1.05
Q3 24
$1.15
$-1.25
Q2 24
$1.16
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACT
ACT
VREX
VREX
Cash + ST InvestmentsLiquidity on hand
$582.5M
$125.6M
Total DebtLower is stronger
$744.5M
$367.6M
Stockholders' EquityBook value
$5.4B
$476.9M
Total Assets
$6.9B
$1.1B
Debt / EquityLower = less leverage
0.14×
0.77×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACT
ACT
VREX
VREX
Q1 26
$125.6M
Q4 25
$582.5M
$155.1M
Q3 25
$545.6M
$152.6M
Q2 25
$616.0M
$223.0M
Q1 25
$639.0M
$212.6M
Q4 24
$602.8M
Q3 24
$674.9M
$200.5M
Q2 24
$711.3M
$190.0M
Total Debt
ACT
ACT
VREX
VREX
Q1 26
$367.6M
Q4 25
$744.5M
$367.5M
Q3 25
$744.1M
$367.5M
Q2 25
$743.8M
$567.2M
Q1 25
$743.4M
$567.0M
Q4 24
$743.0M
Q3 24
$742.7M
$443.4M
Q2 24
$742.4M
$443.1M
Stockholders' Equity
ACT
ACT
VREX
VREX
Q1 26
$476.9M
Q4 25
$5.4B
$472.6M
Q3 25
$5.3B
$455.3M
Q2 25
$5.2B
$549.7M
Q1 25
$5.1B
$540.2M
Q4 24
$5.0B
Q3 24
$5.0B
$529.1M
Q2 24
$4.8B
$581.2M
Total Assets
ACT
ACT
VREX
VREX
Q1 26
$1.1B
Q4 25
$6.9B
$1.1B
Q3 25
$6.9B
$1.1B
Q2 25
$6.8B
$1.4B
Q1 25
$6.7B
$1.3B
Q4 24
$6.5B
Q3 24
$6.6B
$1.2B
Q2 24
$6.3B
$1.3B
Debt / Equity
ACT
ACT
VREX
VREX
Q1 26
0.77×
Q4 25
0.14×
0.78×
Q3 25
0.14×
0.81×
Q2 25
0.14×
1.03×
Q1 25
0.15×
1.05×
Q4 24
0.15×
Q3 24
0.15×
0.84×
Q2 24
0.15×
0.76×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACT
ACT
VREX
VREX
Operating Cash FlowLast quarter
$724.5M
$-16.1M
Free Cash FlowOCF − Capex
$-26.8M
FCF MarginFCF / Revenue
-12.8%
Capex IntensityCapex / Revenue
5.1%
Cash ConversionOCF / Net Profit
-7.00×
TTM Free Cash FlowTrailing 4 quarters
$-13.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACT
ACT
VREX
VREX
Q1 26
$-16.1M
Q4 25
$724.5M
$7.9M
Q3 25
$192.0M
$7.7M
Q2 25
$119.5M
$16.6M
Q1 25
$226.7M
$9.5M
Q4 24
$686.3M
Q3 24
$188.1M
$25.9M
Q2 24
$144.7M
$8.0M
Free Cash Flow
ACT
ACT
VREX
VREX
Q1 26
$-26.8M
Q4 25
$2.3M
Q3 25
$1.4M
Q2 25
$9.8M
Q1 25
$5.3M
Q4 24
Q3 24
$19.9M
Q2 24
$3.3M
FCF Margin
ACT
ACT
VREX
VREX
Q1 26
-12.8%
Q4 25
1.0%
Q3 25
0.7%
Q2 25
4.6%
Q1 25
2.7%
Q4 24
Q3 24
9.7%
Q2 24
1.6%
Capex Intensity
ACT
ACT
VREX
VREX
Q1 26
5.1%
Q4 25
2.4%
Q3 25
3.1%
Q2 25
3.2%
Q1 25
2.1%
Q4 24
Q3 24
2.9%
Q2 24
2.2%
Cash Conversion
ACT
ACT
VREX
VREX
Q1 26
-7.00×
Q4 25
0.65×
Q3 25
Q2 25
2.41×
Q1 25
Q4 24
Q3 24
Q2 24
5.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACT
ACT

Segment breakdown not available.

VREX
VREX

Medical Segment$144.8M69%
Industrial Segment$64.8M31%

Related Comparisons